Stanford Cancer Institute Breakthroughs in Cancer: John Heymach, MD, PhD

Title: Beyond Driver Oncogenes: New Paradigms for Personalizing Lung Cancer Therapies Date: 02.10.2026 As a physician-scientist, Dr. Heymach’s research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for targeted agents and immunotherapy. His research has led to new therapeutic approaches for KRAS mutant lung cancer, small cell lung cancer (SCLC), EGFR mutant non-small cell lung cancer (NSCLC), adenoid cystic carcinoma, and oligometastatic NSCLC, many of which are now considered standard-of-care regimens or undergoing clinical testing. Speaker Intro: 00:12 Talk: 3:15 Audience Q&A: 51:35 Learn more about our Breakthroughs in Cancer seminar series: https://med.stanford.edu/cancer/about... Learn more about the Stanford Cancer Institute: https://med.stanford.edu/cancer Follow the Stanford Cancer Institute LinkedIn:   / stanford-cancer   X:   / scidirector   X:   / stanfordcancer   Instagram:   / stanford.cancer   Subscribe to the Stanford Cancer Institute:    / @stanfordcancerinstitute   #LungCancer #Oncology #Stanford